Cytokine adjuvants: lessons from the past—guidelines for the future?

This publication has 15 references indexed in Scilit:

• Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2
  Published by Elsevier ,2002
• IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism.
  The Journal of Immunology, 1995
• Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.
  Proceedings of the National Academy of Sciences, 1995
• Adjuvants, endocrines and conserved epitopes; factors to consider when designing “herapeutic vaccines”
  International Journal of Immunopharmacology, 1995
• Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1 beta into their sequence.
  The Journal of Immunology, 1993
• Multiple administration with interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV
  Vaccine, 1992
• Interleukin 2 abrogates the nonresponsive state of T cells expressing a forbidden T cell receptor repertoire and induces autoimmune disease in neonatally thymectomized mice.
  The Journal of Experimental Medicine, 1991
• Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma
  European Journal of Cancer and Clinical Oncology, 1990
• Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine.
  Proceedings of the National Academy of Sciences, 1989
• Three‐cell‐type clusters of T cells with antigen‐presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response
  European Journal of Immunology, 1986